3 research outputs found
Role of gut microbiota in obesity
No full textLa microbiota intestinal juega un papel importante entre los múltiples factores que intervienen en el desarrollo de la obesidad. Sabemos que existen diferencias en la composición de la microbiota entre individuos obesos y delgados. El rápido desarrollo en las técnicas de secuenciación de alto rendimiento nos puede permitir desentrañar los mecanismos por los que la disbiosis de la microbiota altera el metabolismo del huésped pero son necesarios más estudios en humanos y una estandarización de los mismos. En cualquier caso, la compleja relación de beneficio mutuo entre microbiota y huésped supone un cambio conceptual en nuestro conocimiento de la biología moderna. Su desarrollo puede llevarnos a nuevas estrategias terapéuticas y de prevención de la obesidad basadas en la modulación de la microbiota intestinal, como la aplicación de dietas que favorezcan una «microbiota sana», el uso de prebióticos y probióticos, o el trasplante de microbiota fecal.Gut microbiota plays an important role among the multiple factors which are involved in the development of obesity. It is already known that there are differences in microbiota's composition between obese and lean individuals. Fast development of high-throughput sequencing methods can allow us to unravel the mechanisms by which microbiota dysbiosis alters host's metabolism. However, further research on humans and its standardisation are still necessary. In any case, the complex relationship of mutual benefit between microbiota and its host implies a conceptual change in our knowledge of modern biology. Its development could lead us to new therapeutic and obesity prevention strategies based on gut microbiota's modulation, such as the implementation of diets which support "healthy microbiota", the use of prebiotics and probiotics, or faecal microbiota transplantation.Grado en Medicin
Multicentre retrospective analysis on pulmonary metastasectomy: an European perspective
No full textOBJECTIVES To assess the current practice of pulmonary metastasectomy at 15 European Centres. Short- and long-term outcomes were analysed.METHODS Retrospective analysis on patients >= 18 years who underwent curative-intent pulmonary metastasectomy (January 2010 to December 2018). Data were collected on a purpose-built database (REDCap). Exclusion criteria were: previous lung/extrapulmonary metastasectomy, pneumonectomy, non-curative intent and evidence of extrapulmonary recurrence at the time of lung surgery.RESULTS A total of 1647 patients [mean age 59.5 (standard deviation; SD = 13.1) years; 56.8% males] were included. The most common primary tumour was colorectal adenocarcinoma. The mean disease-free interval was 3.4 (SD = 3.9) years. Relevant comorbidities were observed in 53.8% patients, with a higher prevalence of metabolic disorders (32.3%). Video-assisted thoracic surgery was the chosen approach in 54.9% cases. Wedge resections were the most common operation (67.1%). Lymph node dissection was carried out in 41.4% cases. The median number of resected lesions was 1 (interquartile range 25-75% = 1-2), ranging from 1 to 57. The mean size of the metastases was 18.2 (SD = 14.1) mm, with a mean negative resection margin of 8.9 (SD = 9.4) mm. A R0 resection of all lung metastases was achieved in 95.7% cases. Thirty-day postoperative morbidity was 14.5%, with the most frequent complication being respiratory failure (5.6%). Thirty-day mortality was 0.4%. Five-year overall survival and recurrence-free survival were 62.0% and 29.6%, respectively.CONCLUSIONS Pulmonary metastasectomy is a low-risk procedure that provides satisfactory oncological outcomes and patient survival. Further research should aim at clarifying the many controversial aspects of its daily clinical practice. Lungs are the most frequent site of metastases of primary tumours located outside the chest cavity [1].This work was supported the European Society of Thoracic Surgeons Biology Club Fellowship 2020. Conflict of interest: Ren�e H. Petersen and Laurens J. Ceulemans disclose financial relationships with Medtronic. Other authors
declare no conflicts of interest
Multicentre retrospective analysis on pulmonary metastasectomy: an European perspective
No full textOBJECTIVES
To assess the current practice of pulmonary metastasectomy at 15 European Centres. Short- and long-term outcomes were analysed.
METHODS
Retrospective analysis on patients ≥18 years who underwent curative-intent pulmonary metastasectomy (January 2010 to December 2018). Data were collected on a purpose-built database (REDCap). Exclusion criteria were: previous lung/extrapulmonary metastasectomy, pneumonectomy, non-curative intent and evidence of extrapulmonary recurrence at the time of lung surgery.
RESULTS
A total of 1647 patients [mean age 59.5 (standard deviation; SD = 13.1) years; 56.8% males] were included. The most common primary tumour was colorectal adenocarcinoma. The mean disease-free interval was 3.4 (SD = 3.9) years. Relevant comorbidities were observed in 53.8% patients, with a higher prevalence of metabolic disorders (32.3%). Video-assisted thoracic surgery was the chosen approach in 54.9% cases. Wedge resections were the most common operation (67.1%). Lymph node dissection was carried out in 41.4% cases. The median number of resected lesions was 1 (interquartile range 25-75% = 1-2), ranging from 1 to 57. The mean size of the metastases was 18.2 (SD = 14.1) mm, with a mean negative resection margin of 8.9 (SD = 9.4) mm. A R0 resection of all lung metastases was achieved in 95.7% cases. Thirty-day postoperative morbidity was 14.5%, with the most frequent complication being respiratory failure (5.6%). Thirty-day mortality was 0.4%. Five-year overall survival and recurrence-free survival were 62.0% and 29.6%, respectively.
CONCLUSIONS
Pulmonary metastasectomy is a low-risk procedure that provides satisfactory oncological outcomes and patient survival. Further research should aim at clarifying the many controversial aspects of its daily clinical practice
